Quote:
Originally Posted by Harry Z
From reading the article, the trial is being conducted to monitor the safety aspect of Tysabri. It didn't mention any data being collected to show what benefit the patients may or may not be getting from taking the drug.
I would hope that patients who have to quit using the drug because of side effects or other problems will end up in the data at the end of 5 years.
Harry
|
Harry,
They are. I read the approach analysis for this trial and Biogen specifically points out that people who have to quit Tysabri will be part of the data analysis.
All results from the 2,500 people in the trial will be used.
-Vic